OverviewSuggest Edit

Arvinas is a biopharmaceutical company focused on developing protein degradation therapeutics for cancers and other diseases. The Company's main product is PROTAC, which degrades and removes disease-causing proteins.

TypePublic
HQNew Haven, US
Websitearvinas.com

Latest Updates

Employees (est.) (Dec 2019)133(+30%)
Revenue (FY, 2019)$43 M(+201%)
Share Price (Sept 2020)$27.4 (+4%)
Cybersecurity ratingBMore

Key People/Management at Arvinas

Timothy Shannon

Timothy Shannon

Chairman of the Board
John G. Houston

John G. Houston

President and Chief Executive Officer
Matthew Batters

Matthew Batters

Vice President, Business Development & Counsel
Angela M. Cacace

Angela M. Cacace

Vice President of Neuroscience and Platform Biology
Sean Cassidy

Sean Cassidy

Chief Financial Officer
John A. Grosso

John A. Grosso

Vice President of Chemistry, Manufacturing, and Controls
Show more

Arvinas Office Locations

Arvinas has an office in New Haven
New Haven, US (HQ)
5 Science Park
Show all (1)

Arvinas Financials and Metrics

Arvinas Revenue

Arvinas's revenue was reported to be $42.98 m in FY, 2019
USD

Revenue (Q2, 2020)

5.7m

Net income (Q2, 2020)

(25.2m)

EBIT (Q2, 2020)

(26.5m)

Market capitalization (16-Sept-2020)

1.1b

Closing stock price (16-Sept-2020)

27.4

Cash (30-Jun-2020)

21.6m

EV

1.1b
Arvinas's current market capitalization is $1.1 b.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Revenue

6.7m7.6m14.3m43.0m

Revenue growth, %

14%

General and administrative expense

3.2m3.5m12.9m27.3m

R&D expense

19.9m28.8m45.2m67.2m
Quarterly
USDQ3, 2017Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

1.7m3.4m4.0m4.0m30.1m6.2m5.7m

General and administrative expense

857.3k4.3m5.6m6.4m8.0m7.9m8.8m

R&D expense

7.2m13.1m14.2m16.0m16.6m21.7m23.4m

Operating expense total

8.1m17.4m19.8m22.4m24.5m29.7m32.2m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Cash

5.1m30.9m3.2m9.2m

Accounts Receivable

25.0m2.8m6.3m

Prepaid Expenses

1.4m316.9k2.8m3.7m

Current Assets

37.3m65.5m195.7m290.9m
Quarterly
USDQ3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

6.2m28.8m11.3m12.1m36.1m21.6m

Accounts Receivable

2.5m1.4m59.3k3.9m3.6m

Prepaid Expenses

3.5m2.3m2.7m4.0m3.5m3.3m

Current Assets

95.5m179.7m163.3m199.7m270.2m249.6m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(14.4m)(24.0m)(41.5m)(70.3m)

Depreciation and Amortization

436.3k347.4k706.0k1.6m

Accounts Payable

1.2m(969.5k)2.0m1.6m

Cash From Operating Activities

(19.4m)5.1m(16.1m)(40.6m)
Quarterly
USDQ3, 2017Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(19.3m)(25.4m)(14.4m)(31.6m)(49.2m)(21.7m)(47.0m)

Depreciation and Amortization

246.4k483.1k246.2k556.6k1.0m617.5k1.3m

Accounts Payable

(648.0k)704.2k(1.7m)(1.4m)(619.0k)(1.9m)(2.3m)

Cash From Operating Activities

(23.0m)(3.9m)(12.7m)(26.3m)(24.4m)(16.9m)(38.4m)
USDFY, 2016

Financial Leverage

-1.2 x
Show all financial metrics

Arvinas Acquisitions / Subsidiaries

Company NameDateDeal Size
Arvinas Androgen Receptor
Arvinas BRD4
Arvinas Estrogen Receptor
Arvinas Winchester

Arvinas Cybersecurity Score

Cybersecurity ratingPremium dataset

B

89/100

SecurityScorecard logo

Arvinas Online and Social Media Presence

Embed Graph

Arvinas News and Updates

Arvinas to Present at the Citi 15th Annual BioPharma Virtual Conference

NEW HAVEN, Conn., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Ian Taylor, Ph.D., Chief Scientific Officer, will participate in a fireside chat at th…

Arvinas Reports Second Quarter 2020 Financial Results and Provides Corporate Update

NEW HAVEN, Conn., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biopharmaceutical company creating a new class of drugs based on targeted protein degradation, today reported financial results for the second quarter ended June 30, 2020 and provided a corporate upd…

Arvinas to Present Virtually at the Goldman Sachs 41st Annual Global Healthcare Conference

NEW HAVEN, Conn., June 05, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Ron Peck, M.D., Chief Medical Officer, will participate in a fireside chat at the Goldm…

Arvinas Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

NEW HAVEN, Conn., March 16, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the fourth quarter and full year ended December 31, 2019 and provided …

Arvinas to Present at the 31st Annual Piper Jaffray Healthcare Conference

NEW HAVEN, Conn., Nov. 27, 2019 (GLOBE NEWSWIRE) -- Arvinas Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Ian Taylor, Ph.D., Chief Scientific Officer, will participate in a fireside chat at the 31st Annual Pip…

Arvinas Appoints Laurie Smaldone Alsup, M.D., to Board of Directors

Dr. Smaldone Alsup Brings Additional Product Commercialization and Global Regulatory Experience Dr. Smaldone Alsup Brings Additional Product Commercialization and Global Regulatory Experience
Show more

Arvinas Blogs

Arvinas Reports First Quarter 2020 Financial Results and Provides a Corporate Update

Arvinas Reports First Quarter 2020 Financial Results and Provides a Corporate Update Content Import Tue, 04/28/2020 - 07:00 Arvinas Reports First Quarter 2020 Financial Results and Provides a Corporate Update April 28, 2020 at 7:00 AM EDT This release is a bac…

Arvinas Provides Update on Business Continuity Related to the Impact of the COVID-19 Pandemic

NEW HAVEN, Conn., April 13, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today provided an update regarding the impact of the COVID-19 pandemic on its overall business continuity,

Arvinas to Present at the American Society of Clinical Oncology Annual Meeting

Arvinas to Present at the American Society of Clinical Oncology Annual Meeting Content Import Tue, 03/31/2020 - 07:00 Arvinas to Present at the American Society of Clinical Oncology Annual Meeting March 31, 2020 at 7:00 AM EDT This release is a backfill from a…

Arvinas, Inc. Announces Proposed Offering of Common Stock

NEW HAVEN, Conn. , Nov. 06, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that it is commencing an underwritten public offering of $90.0 million of shares of its common stock.  In

Arvinas to Present Initial Data from Ongoing Clinical Trials and a Pipeline Update at the 2nd Targeted Protein Degradation Summit

Platform Presentation to Include Initial Safety, Tolerability, and Pharmacokinetic Data from Ongoing Phase 1 Trials Neuroscience Presentation to Include Data from Preclinical Tau and Alpha-Synuclein Programs NEW HAVEN, Conn. , Oct. 17, 2019 (GLOBE NEWSWIRE) -- Arvinas Inc.

Arvinas Strengthens Scientific Advisory Board with Leaders in Oncology and Neurological Disorders

NEW HAVEN, Conn. , Oct. 02, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, announced that six new thought leaders will join the company’s scientific advisory board (SAB).
Show more

Arvinas Frequently Asked Questions

  • Who are Arvinas key executives?

    Arvinas's key executives are Timothy Shannon, John G. Houston and Matthew Batters.

  • How many employees does Arvinas have?

    Arvinas has 133 employees.

  • What is Arvinas revenue?

    Latest Arvinas annual revenue is $43 m.

  • What is Arvinas revenue per employee?

    Latest Arvinas revenue per employee is $323.1 k.

  • Who are Arvinas competitors?

    Competitors of Arvinas include Luzitin, Dauntless Pharmaceuticals and Actuate Therapeutics.

  • Where is Arvinas headquarters?

    Arvinas headquarters is located at 5 Science Park, New Haven.

  • Where are Arvinas offices?

    Arvinas has an office in New Haven.

  • How many offices does Arvinas have?

    Arvinas has 1 office.